Drugs / XL999
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00955084 | Aug 2008 → May 2010 | cancer | Symphony Evolution, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00491699 | Aug 2007 → Jan 2008 | non-small cell lung carcinoma | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00104117 | Nov 2004 → Sep 2008 | cancer | Symphony Evolution, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00322673 | May → Nov 2006 | acute myeloid leukemia | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00304590 | Feb → Dec 2006 | plasma cell myeloma | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00277290 | Jan → Nov 2006 | ovarian cancer | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00277316 | Dec 2005 → Feb 2007 | renal cell carcinoma | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00277329 | Dec 2005 → Aug 2007 | non-small cell lung carcinoma | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00277303 | Dec 2005 → Aug 2006 | colorectal cancer | Symphony Evolution, Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01945164 | Apr 2010 → Jun 2012 | cancer | John Sarantopoulos | No longer available | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XL999 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00304590 ↗ |
| Action | Inhibit | “small molecule inhibitor of multiple kinases” NCT00277290 ↗1“Stem cell growth factor receptor inhibitor” CHEMBL5314391 ↗ |
| Modality | Small molecule | “XL999 is a small molecule inhibitor of multiple kinases” NCT00277290 ↗ |
| Route | Intravenous | “XL999 Administered Intravenously to Subjects With Solid Tumors” NCT00104117 ↗ |
| Target | FLT3 | “XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC.” NCT00322673 ↗ |
| Target | KDR | “XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC.” NCT00322673 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL5314391 ↗ |
| Target | SRC | “XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC.” NCT00322673 ↗ |